Management of patients with hematologic malignancy (HM) with fever is complex as illustrated by recent guidelines for the use of antimicrobial agents in neutropenic patients with cancer [1] . This complexity arises from the inability to determine whether the fever is related to an infection or reflects other causes, including blood transfusions, medications, tumor burden, or other complications such as diffuse alveolar hemorrhage [2, 3] . HMs are usually associated with febrile presentations such as in lymphoma and graftvs-host disease in stem cell recipients [4] [5] [6] . Another important issue in HM patients is the severe infections caused by low inocula of bacteria or fungi that cannot be detected using routine cultures alone. Therefore, relying on clinical presentation or microbiologic cultures limits the ability of healthcare professionals to determine the cause of fever in these patients and leads to the heavy use of empiric and often unnecessary antimicrobial therapy and consequently leading to the emergence of resistant organisms.
In view of these issues, researchers have attempted to evaluate the effectiveness of certain biomarkers that help make proper clinical decisions in febrile patients [7] [8] [9] [10] [11] [12] [13] [14] . They have become increasingly interested in molecular tests for diagnostic and prognostic purposes, with recent growing attention to procalcitonin (PCT) and pro-adrenomedullin (proADM), particularly in critically ill patients [2, [15] [16] [17] . These 2 biomarkers are valuable because neither of them are neutrophil specific or derived exclusively by the adrenal (pro-adrenomedullin) or C cells of the thyroid (procalcitonin), and therefore the assay should still be valid even in the presence of profound neutropenia.
Various studies have found PCT to be an acceptable biomarker for predicting bloodstream infections: AppData/Local/ Microsoft/Windows/ryhachem/Local Settings/Temporary Internet Files/Content.Outlook/R4C23Q9C/ProADM and PCT (5) .docx -_ENREF_3#_ENREF_3 (BSIs) and often useful in determining infectious and noninfectious causes of fever [2, 3, 17, 18] . It was also useful in differentiating fever caused by systemic infections from fever caused by noninfectious etiologies in neutropenic patients [19] . Other investigators found that PCT is a good indicator of sepsis in the intensive care unit (ICU) or emergency setting [18, 20] . PCT was also investigated as a guide for determining the appropriateness of antibiotic therapy and response to treatment [17, [21] [22] [23] [24] .
ProADM was studied and found to have varied predictive and prognostic role in pulmonary, cardiovascular, and rheumatologic diseases [25, 26] . In one study, proADM proved to be a prognostic factor in critically ill patients with sepsis [16] . This raised the possibility of proADM being a valuable predictor of infection in cancer patients, particularly those with HMs.
To date, no large studies have investigated and compared the roles of proADM and PCT for prediction and diagnosis of infections in febrile HM patients; therefore, in the present study, we aimed to evaluate these 2 markers in this setting.
METHODS
At The University of Texas MD Anderson Cancer Center, 340 febrile consecutive patients with HMs were enrolled in this study from June 2009 to December 2010. Only one episode per patient was included. Critically ill HM patients admitted to the ICU were excluded from this study since they were included in a separate study evaluating critically ill cancer patients [27] . Using a Kryptor analyzer, proADM and PCT levels were measured using residual plasma samples within 24 hours of fever onset and then 4-7 days afterward. For proADM the lower limit of detection is 0.05 nmol/L; however, the lower limit of quantitation is 0.23 nmol/L. There is no stated upper limit because a reading of >100 nmol/L is sent back into the cycle and automatically diluted for a more accurate reading [28] . For PCT the lower limit of detection is 0.06 ng/mL; however, the lower limit of quantitation is 0.075 mg/mL. There is no stated upper limit because a reading of >50 ng/mL is sent back into the cycle and automatically diluted for a more accurate reading [29] . Data collected included demographic and clinical information including: underlying malignancy, date of admission, past medical history, vital signs, date of defervescence, presence and duration of neutropenia, pertinent radiologic imaging findings, microbiologic data, and antimicrobial therapy administered at the onset of fever. The study protocol was approved by the MD Anderson Institutional Review Board, and a waiver of informed consent was obtained.
Definitions
Fever was defined as temperature of ≥38.3°C or 2 consecutive readings >38°C. Systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock definitions were based on those agreed upon by the consensus panel of the American College of Chest Physicians and Society of Critical Care Medicine and the published modifications by Annane and colleagues [30] . SIRS was defined as the presence of 2 or more of the following conditions: temperature >38.5°C or <35°C, heart rate >90 beats/minute, respiratory rate >20 breaths/minute and white blood cell count (WBC) >12 000 cells/ mL, <4000 cells/mL, or >10% immature (band) forms [31] . Definite sepsis included sepsis, severe sepsis, and septic shock in the presence of a microbiologically documented infection (culture or Gram stain of blood, sputum, urine, or normally sterile body fluid positive for a pathogenic microorganism) [30, 32] . Bacteremia was defined by positive blood cultures associated with fever as a clinical manifestation of infection. Localized infection was indicated by the presence of a localized infection without BSI. Response to antimicrobial therapy was defined as defervescence or eradication of infection according to a documented negative follow up culture within 96 hours after initiation of treatment. Neutropenia was defined as an ANC of <500 cells/mm 3 
according to the Infectious Diseases
Society of America 2011 clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer [1] .
Statistical Methods
Wilcoxon rank sum tests were used to compare initial proADM values as well as initial PCT values between 2 different groups of patients. Kruskal-Wallis tests were used to compare initial proADM as well as initial PCT values among 3 different groups of patients. If a significant result (P < .05) was detected for a Kruskal-Wallis test, then Wilcoxon rank sum tests were used for the pairwise comparisons. The α levels of the post hoc pairwise comparisons were adjusted using a sequential Bonferroni method to control for type I error. Patients' initial and follow-up proADM values as well as PCT values were compared using signed rank tests. The diagnostic performance of proADM and PCT biomarkers for various infections was assessed. First, the area under the receiver operating characteristic (ROC) curve was evaluated and compared between the 2 biomarkers. Next, the optimal cutoff value for each biomarker was determined on the basis of its ROC curve. Then sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios were calculated based on their definitions. All tests except those in pairwise comparisons were 2-sided at a significance level of .05. The statistical analyses were performed using SAS version 9.3 (SAS Institute Inc, Cary, NC).
RESULTS
Serum PCT and proADM levels were measured at the onset of fever and during follow-up 4-7 days later. We did not measure the proADM levels in 20 patients at onset and 11 patients during follow-up owing to a lack of plasma samples.
Patients' Demographic and Clinical Data
During the study period, 340 febrile hematologic malignancy patients were identified. The demographic and clinical characteristics of these patients are shown in Table 1 . The number of neutropenic patients at onset of fever was 197 (58%), and the number of those who were neutropenic during enrollment was 232 (68%).
Initial ProADM and PCT Levels
The median initial PCT levels in patients with definite sepsis, SIRS, and no sepsis were 0.35 ng/mL (range, 0.075-129.300 ng/mL), 0.25 ng/mL (range, 0.075-23.820 ng/mL), and 0.18 ng/mL (range, 0.075-67.380 ng/L), respectively. These levels were significantly different (P < .001). Initial PCT levels were significantly higher in patients with definite sepsis and SIRS than in those with no sepsis (P < .0001 and P = .017, respectively). However, PCT levels were not significantly different between patients with definite sepsis than those with SIRS (P = .08). The median proADM levels at enrollment in patients with definite sepsis, SIRS, and no sepsis tended to be different (P = .06) at the following respective levels of 0.91 nmol/L (range, 0.05-8.78 nmol/L), 0.68 nmol/L (range, 0.05-3.60 nmol/L), and 0.79 nmol/L (range, 0.05-6.48 nmol/L). Unlike PCT, proADM levels were significantly higher in patients with definite sepsis than in those with SIRS (P = .023; Figure 1 ). The median initial PCT level in patients with no documented infections (0.24 ng/mL [range, 0.075-67.380 ng/mL]) was significantly lower than that in patients with BSIs (0.42 ng/mL [range, 0.075-129.300 ng/mL]; P = .013). However, the median PCT level in patients with localized bacterial infections (0.24 ng/mL [range, 0.075-7.96 ng/mL]) was similar to that in patients without documented infections (0.24 ng/mL [range, 0.075-67.380 ng/mL]; P = .96). On the other hand, the initial proADM levels were not only significantly higher in patients with Stem cell transplant 91 (27) Median WBC at onset of fever, (range) In neutropenic patients, results showed that both the median PCT (0.39 ng/mL [range, 0.075-58.13 ng/mL]) and median proADM (0.87 nmol/L [range, 0.05-3.35 nmol/L]) levels were significantly higher in patients with BSIs compared to those with no infection (P = .011, P = .01 respectively). This was not the case in nonneutropenic patients, where the levels of PCT or proADM were similar in patients with BSI, localized bacterial infections, or no infections.
The performances of proADM and PCT for discriminating bacterial infections (BSI and localized infections) from no infections were calculated. The area under the ROC curve was 0.6010 for proADM and 0.5417 for PCT with no statistically significant difference (Figure 3) . The best diagnostic efficiency of these tests to detect infections (BSIs and localized infections) was observed when either of these tests was positive with a sensitivity of 78%, a negative predictive value (NPV) of 69%, and a positive likelihood ratio of 1.2 (Table 2) . Furthermore, when we lowered the cutoff value to 0.10 ng/mL for PCT and 0.35 nmol/L for proADM, we were able to get a higher sensitivity of 99% and a NPV of 80%.
Follow-up ProADM and PCT Levels
We measured the patients' proADM and PCT levels 4-7 days after antimicrobial treatment. The median follow-up proADM and PCT levels in patients with bacterial infections (BSI and Figure 1 . Initial pro-adrenomedullin and procalcitonin levels in patients with definite sepsis, patients with systemic inflammatory response syndrome, and patients with no sepsis, on a logarithmic scale. Abbreviations: PCT, procalcitonin; proADM, pro-adrenomedullin; SIRS, systemic inflammatory response syndrome. localized), who responded to therapy, dropped from 0.95 nmol/L to 0.84 nmol/L (P = .007) and from 0.27 ng/mL to 0.19 ng/mL (P = .002) respectively, whereas, in patients who did not respond to therapy, there was no significant change between the proADM and PCT initial and follow-up levels (P = .61 and P = .77, respectively).
DISCUSSION
This study is novel in its evaluation of the role of proADM compared to PCT as diagnostic and prognostic biomarkers of infection in a large cohort of febrile non-critically ill patients with HMs. Our results suggest that proADM was a good predictor of localized infections. In contrast, PCT was not clinically useful in identifying such infections. However, PCT had a better yield in gram-negative bacterial infections, where it was able to differentiate BSI from localized infections or no infections. PCT was a good diagnostic marker to predict the absence of sepsis but did not differentiate between definite sepsis and SIRS; however, proADM has the advantage of differentiating between definite sepsis and SIRS. Both proADM and PCT were good at differentiating BSI infections from no infections in neutropenic patients only. Because it is often difficult to detect localized infections or to differentiate SIRS from sepsis in HM patients given the low yield of cultures in this patient population, proADM might be a more useful biomarker of infections and sepsis in HM patients. The better diagnostic value of these tests to predict infections (BSI and localized infections) is when either of these tests is positive. We also showed that both proADM and PCT were good indicators of response to antimicrobial therapy in patients with bacterial infections (BSI or localized).
Several studies have assessed PCT as a biomarker of infection in different patient populations and settings. In some of these studies, results similar to ours were observed in that PCT levels in patients with bacteremia were significantly higher than in those with localized infections [11, 33, 34] . Furthermore, 3 studies in febrile neutropenic patients had similar findings to ours in that PCT was a good marker of documented BSIs [15, 35, 36] , but BSIs reveal themselves through positive culture in all patients including HM patients. Therefore, the failure of PCT to detect localized infections is a major deficiency. However, the ability of both PCT and proADM to detect BSIs in febrile neutropenic patients has important implication when they present to Abbreviations: LR (−), negative likelihood ratio; LR (+), positive likelihood ratio; NPV, negative predictive value; PCT, procalcitonin; PPV, positive predictive value; proADM, pro-adrenomedullin.
emergency care whereby if they have high PCT and proADM levels, these patients should be considered for admission. Several studies have shown that PCT has a better yield for gram-negative infections, and this was found to be true in our study only in the setting of BSIs [37] [38] [39] [40] . Unlike PCT, proADM has been shown in this current study to be an excellent predictor of localized bacterial infections and would be a more useful indicator for antibiotic treatment of localized infections. This is of paramount importance in HM patients, where localized infections could be undetectable by conventional microbiologic techniques. This finding is further supported by reports in the literature showing that proADM is one of the biomarkers that can help predict the severity of and prognosis for lower respiratory tract infections and community-acquired pneumonia [41, 42] .
A small study showed results similar to ours in that PCT failed to discriminate between infections and inflammatory complications of the transplants [43] . In comparison, investigators have not studied proADM in the complex HM patient population as a biomarker of infection and sepsis. In a large study of 101 critically ill patients, researchers observed that proADM was a good biomarker for differentiation of sepsis from SIRS, which is similar to our observation [16] . Another study in our center involving critically ill cancer patients showed similar findings to the above study [27] . Other studies assessing the usefulness of proADM as a biomarker in infections showed that higher levels of proADM are associated with a poor prognosis [25, 44] . When studying the value of markers in determining response to therapy, investigators found that PCT levels dropped significantly in patients with documented infections that responded to therapy [33] . In the present study, we also found that follow-up levels of both proADM and PCT dropped significantly in those who responded to therapy whether they had BSIs or localized infections. The use of PCT-based guidelines for initiation of antibiotic therapy substantially reduced the use of antimicrobials without affecting treatment outcome [45, 46] .
PCT's capacity as diagnostic and prognostic biomarker is thoroughly covered in the literature, but proADM remains the most novel biomarker for prediction of infections in HM patients. Finally, implementation of a cancer care plan that uses proADM and PCT measurement in febrile patients should be studied in randomized controlled trials. These studies may provide clinicians with scientifically sound methods of identifying causes of fever that can complement their clinical judgment and help them attain improved antibiotic stewardship.
Our study had several limitations. The observational design where we collected clinical data, retrospectively, may have masked confounding variables. This was a single-center study, and the majority of patients were white, both of which may have limited generalization of the results. Exclusion of the critically ill patients also limits the generalization of the results.
In conclusion, proADM and PCT both have promising roles in assisting clinicians in recognizing BSIs and sepsis in febrile HM patients in a timely manner and determine their response to therapy. ProADM has the unique advantage of predicting localized infections, which is extremely important because BSIs can be easily identified by blood cultures, whereas localized infections are sometimes occult and hard to detect. Another advantage of proADM is its ability to differentiate between sepsis and SIRS, which has a great implication in patients with HMs. These findings are of paramount importance since fever due to SIRS is very common in this patient population and could be related to diffuse alveolar hemorrhage, chemotherapy-related hepatitis, or graft vs host disease. In addition, the microbiologic cultures often fail in detecting sepsis or differentiating between SIRS associated with these inflammatory conditions vs sepsis associated with low inocula infections. Decreasing levels of these biomarkers in patients responding to antimicrobial therapy may prevent unnecessary prolonged course of therapy and may have a role in antibiotic stewardship.
Notes

